Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a glo | Embecta ...
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint. | Genentech has ...
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve its position, mapping out a possible shift from therapeutics to the defense sector. | Phage-focused BiomX is ...
North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. | North Carolina-based contract research organization ...
MiniMed is out to prove it deserves the name, with a new FDA clearance for its smallest insulin pump yet. | At about half the size of the 780G pump, the shape of the 300-unit MiniMed Flex is ...
As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...
Endovascular robot developer XCath said it has successfully completed its first remotely operated stroke procedure, linking a neurosurgeon with a patient more than a hundred miles away.
With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...
More than 100 marchers took to Capitol Hill on Wednesday, carrying a coffin to the FDA in a symbolic protest highlighting lives they say could be lost to regulatory delays affecting a group of rare ...
Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.
Stroke treatment hardware developer Imperative Care has posted a $100 million funding round to support its commercial growth and research into its upcoming robotic platform. | The former Fierce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results